Moderna to pay up to $2.25B to end mRNA vaccine patent dispute
Thursday, March 12, 2026
2 min read
Canonical SourceUSA
Summary Only
What Changed
Moderna will pay up to $2.25 billion to Arbutus Biopharma and Genevant Sciences, settling a long-standing patent dispute concerning mRNA vaccine technology.
Key Figures
$2.25 billionto Arbutus Biopharma and Roivant subsidiary Genevant Science
Sigvera Intelligence
Source Trust:Discovery
Source Report
Moderna has agreed to pay up to $2.25 billion to Arbutus Biopharma and Roivant subsidiary Genevant Sciences to settle a patent dispute over mRNA vaccine technology.
Industry Context
Healthtech & Biotech
Where this signal fits in the broader landscape.
115 industry signalsRegulatory & Policy
Source Verification
Verified from official source
Publisher—
Publication DateMar 12, 2026
Source ClassVerified Canonical
Signal Timeline
First ReportedMar 12, 2026
IndexedMar 12, 2026
PublishedMar 12, 2026
https://www.biopharmadive.com/news/moderna-roivant-arbutus-genevant-patent-settlement-mrna-vaccines/813792/
Read Full SourceGet cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
Sign In